Sg3 Management, LLC Editas Medicine, Inc. Call Options Transaction History

Sg3 Management, LLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2021 Aug 16, 2021	SELL	$31.29 - $56.64 $8.26 Million - $14.9 Million	-263,900 Reduced 44.81%	325,000 $18.4 Million
Q1 2021 May 17, 2021	BUY	$39.71 - $90.58 $13.5 Million - $30.7 Million	338,900 Added 135.56%	588,900 $24.7 Million
Q4 2020 Feb 16, 2021	BUY	$27.07 - $84.35 $4.95 Million - $15.4 Million	183,000 Added 273.13%	250,000 $17.5 Million
Q3 2020 Nov 13, 2020	BUY	$28.06 - $37.16 $1.6 Million - $2.12 Million	57,000 Added 570.0%	67,000 $1.88 Million
Q2 2020 Aug 14, 2020	BUY	$18.5 - $34.34 $92,500 - $171,700	5,000 Added 100.0%	10,000 $296,000
Q1 2020 May 12, 2020	BUY	$14.88 - $32.78 $74,400 - $163,900	5,000 New	5,000 $99,000

248

57M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $151M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Sg3 Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg3 Management, LLC with notifications on news.